Arcera Life Sciences, a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group, an innovation-driven global pharmaceutical and healthcare group, have announced the signing of a Memorandum of Understanding (MoU) to establish a long-term strategic collaboration focused on licensing, technology development, neuroscience innovation and value creation in the global life sciences sector.
The collaboration combines Fosun Pharma's world-class R&D and manufacturing capabilities with Arcera's international market access and commercial infrastructure, positioning Abu Dhabi as a premier bridge between Chinese biotech innovation and global markets while accelerating patient access to breakthrough therapies across the Middle East and beyond.
The collaboration will initially focus on identifying potential licensing opportunities for Fosun Pharma assets in oncology, neuroscience, rare diseases and cardiometabolic disease, including compounds currently in advanced clinical development or commercial stages in China. The neuroscience collaboration will focus particularly on neurodegenerative diseases, including Alzheimer's disease programs, addressing a critical global health challenge where both innovative therapeutics and regional access remain significant unmet needs.
There will be focus on exploration of joint ventures or new entities to localise cutting-edge biotechnology and foster sovereign R&D capabilities in the UAE across small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.
